Epidemic

HOUSING WORKS COMMEMORATES WORLD AIDS DAY & ANNOUNCES OPENING OF NEW WESTSIDE COMMUNITY HEALTH CENTER

Retrieved on: 
Friday, December 1, 2023
Diamond, Epidemic, World AIDS Day, Housing Works, HIV/AIDS, Housing, Psychiatry, Mandarin Oriental Hotel Group, AIDS, Name, New Yorker

NEW YORK, Dec. 1, 2023 /PRNewswire/ -- Housing Works, a NYC non-profit organization that provides advocacy, support and lifesaving services to those impacted by homelessness and HIV/AIDS, announced the opening of a new health care center and its list of priorities for Ending the Epidemic to commemorate World AIDS Day 2023.  The initiatives will be outlined at a press conference joined by a roster of local officials and community leaders at AIDS Memorial Park in Manhattan at 11am on Friday, December 1,2023, World AIDS Day.  The press conference will be immediately followed by a public "Reading of the Names" ceremony to honor New Yorkers who have lost their lives to AIDS by reading their names aloud; and to recommit to action and advocacy to end the epidemic worldwide.

Key Points: 
  • The initiatives will be outlined at a press conference joined by a roster of local officials and community leaders at AIDS Memorial Park in Manhattan at 11am on Friday, December 1,2023, World AIDS Day.
  • The Westside Community Health Center, located at 326 W. 48th Street, is a newly renovated space designed to deliver a more comprehensive and comfortable experience of care to New Yorkers in need.
  • Housing Works will host a ribbon-cutting and tours on December 13 starting at 10am to celebrate the opening.
  • "Our new health center will provide comprehensive healthcare services including primary care, behavioral health, psychiatry, sexual wellness, and more, and all clients will benefit from Housing Works' other integrated supportive services including care management.

3800 MHz wireless spectrum auction - Quebecor and Videotron invest nearly $300 million to move forward with Canadian expansion

Retrieved on: 
Friday, December 1, 2023
Pandemic, Acquisition, Mobile virtual network operator, Financial statement, Face, Economic development, Freedom Mobile, Telecommunications, Investment, Corporation, Epidemic, Public expenditure, Hertz, Advertising, Vidéotron, Effervescence, Analysis, Groupe TVA, MVNO, Government, Cable television, Risk management, Freedom, Science, Quebecor

"It is further proof that we have not only the will but also the ability to achieve our goals, for the benefit of consumers.

Key Points: 
  • "It is further proof that we have not only the will but also the ability to achieve our goals, for the benefit of consumers.
  • Canadians have already seen a significant drop in the price of wireless services, thanks to the healthy competition created by Videotron's acquisition of Freedom Mobile."
  • Approximately 61% of the 305 blocks of wireless spectrum acquired by Quebecor are located outside Québec, mainly in southern Ontario, Alberta and British Columbia.
  • Quebecor also bought spectrum in Manitoba, where it now holds a total of 46 blocks in the 600, 3500 and 3800 MHz bands as it prepares to enter that market.

ATI targets 2027 revenue exceeding $5 billion on platform of organic growth

Retrieved on: 
Wednesday, November 29, 2023
Pandemic, EBITDA, Terrorism, NYSE, Security (finance), Annual report, Share repurchase, Chairperson, Electronics, Epidemic, Burn, Multimedia, Science, GAAP, A&D, Growth, Risk, News, Real estate, Renewable energy

NEW YORK, Nov. 29, 2023 /PRNewswire/ -- At its 2023 Investor Update, ATI Inc. (NYSE: ATI) forecast revenues exceeding $5 billion with adjusted EBITDA of $1 billion by 2027. "As we close out a successful 2023, ATI is well-positioned to significantly increase cash generation and deployment to shareholders over the next four years," said Robert S. Wetherbee, Board Chair and CEO. The company projects more than $1 billion in top-line organic growth and a 60% increase in adjusted earnings from 2023 to 2027. "ATI's aerospace and defense foundation, the majority of which is secured through long term agreements, sets the stage for continued growth and value creation," said Wetherbee.

Key Points: 
  • Company leaders to share insights into expanding A&D business, affirm long-term strategy
    NEW YORK, Nov. 29, 2023 /PRNewswire/ -- At its 2023 Investor Update, ATI Inc. (NYSE: ATI) forecast revenues exceeding $5 billion with adjusted EBITDA of $1 billion by 2027.
  • The company projects more than $1 billion in top-line organic growth and a 60% increase in adjusted earnings from 2023 to 2027.
  • Estimated revenue between $4.5 and $4.6 billion dollars.
  • "And the results are clear: we're gaining share, expanding capacity and capabilities, and increasing shareholder value, well-positioned for growth."

Mindbloom Launches Expert-Led Psychedelic Therapy for Heartbreak, Burnout, and more

Retrieved on: 
Wednesday, November 29, 2023
Attention, Depression, TED, Addiction, Epidemic, Medicine, Anxiety, Diagnosis, Partnership, Rejection, Mental health, DSM-IV codes, Failure, Loneliness, Face, Pharmaceutical industry, Nursing, Series

AUSTIN, Texas, Nov. 29, 2023 /PRNewswire/ -- Mindbloom, the largest provider of psychedelic medicine, today announced the launch of its Mastermind Series – the first expert-led psychedelic therapy programs for overcoming heartbreak, burnout, and other mental health challenges. Each program was developed in partnership with a leading expert in the field, and combines their specialized teachings with ketamine therapy to enhance neuroplasticity and enable lasting change.

Key Points: 
  • AUSTIN, Texas, Nov. 29, 2023 /PRNewswire/ -- Mindbloom , the largest provider of psychedelic medicine, today announced the launch of its Mastermind Series – the first expert-led psychedelic therapy programs for overcoming heartbreak, burnout, and other mental health challenges.
  • Each program was developed in partnership with a leading expert in the field, and combines their specialized teachings with ketamine therapy to enhance neuroplasticity and enable lasting change.
  • "More than 100 studies and 20+ years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today," said Mindbloom CEO and Founder Dylan Beynon.
  • The Mastermind Series is available to new and returning clients who receive a diagnosis of anxiety or depression.

ST Pharm Presented '100-Day Expedite Strategy', Preparedness and Proactive Measures for Future Pandemic at Korea-CEPI R&D Workshop

Retrieved on: 
Tuesday, November 21, 2023
CEPI, LMIC, Epidemic, DNA, Technology transfer, CDMO, IVT, IND, FIH, Biotechnology, Vaccine, Infection, Messenger, Therapy, Coalition, LNP, Small RNA, AER, RNA

During the main speaker session, Joo-Sung James Yang, Ph.D., SVP Head of Biotechnology R&D at ST Pharm, addressed the strategy, which aims to develop pandemic vaccines against emerging infectious diseases within 100 days.

Key Points: 
  • During the main speaker session, Joo-Sung James Yang, Ph.D., SVP Head of Biotechnology R&D at ST Pharm, addressed the strategy, which aims to develop pandemic vaccines against emerging infectious diseases within 100 days.
  • ST Pharm highlighted its mRNA platform technologies as a key success factor of '100-Day Expedite Strategy', which are proprietary 5'-capping analogs, marketed as SmartCap®, and LNP drug delivery system, STLNP®.
  • Also, ST PHARM has two different RNA therapeutic biotech companies in the United States, which creates synergistic effects on both CDMO business and new drug/vaccine development.
  • -Vernagen (Atlanta, USA) specialized in the development of mRNA vaccines and antibody-encoding RNA (AER) platform technology for infectious diseases.

Universal Technical Institute Reports Fiscal Year 2023 Fourth Quarter and Year-End Results

Retrieved on: 
Wednesday, November 15, 2023
EBITDA, Disclosure, Acquisition, Employment, Universal Technical Institute, Security (finance), Bank statement, Student, Depreciation, Public expenditure, Strategic planning, Epidemic, Concorde, UTI, Social media, COVID-19, Disease, GAAP, Veteran, Credit, School, Regulation Fair Disclosure, Forecasting, Total, Table, EST, Growth, Congress, Regulation, Failure, Bank, Online shopping, Bookkeeping

Fiscal 2023 reflects UTI results for the full year and Concorde results beginning December 1, 2022.

Key Points: 
  • Fiscal 2023 reflects UTI results for the full year and Concorde results beginning December 1, 2022.
  • For the Company's most recent investor presentation and quarterly financial supplement, please see its investor relations website at https://investor.uti.edu .
  • Management will hold a conference call to discuss the financial results for the fiscal 2023 fourth quarter ended September 30, 2023, on Wednesday, November 15, 2023 at 4:30 pm EST.
  • A live webcast of the call will be available via the Universal Technical Institute investor relations website at https://investor.uti.edu .

Novanta Announces Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 7, 2023
Other Health, General Health, Machinery, Robotics, Technology, Medical Devices, Other Manufacturing, Health Technology, Engineering, Medical Supplies, Other Technology, Health, Manufacturing, Adjustment, Element, Sale, Adjusted gross income, Security (finance), Event, Tax, Public expenditure, Cyprus Securities and Exchange Commission, News, GAAP, Acquisition, Net income, Software, Social, Growth, Epidemic, EPS, Risk, Tax rate, Seizure, Pandemic, Forecasting, Benefit, Annual report, Table, Failure, Social Security Government Pension Offset, Bank, Video game, Film industry, Bookkeeping, Risk management, Novantae

In the third quarter of 2023, GAAP operating income was $30.3 million, compared to $28.7 million in the third quarter of 2022.

Key Points: 
  • In the third quarter of 2023, GAAP operating income was $30.3 million, compared to $28.7 million in the third quarter of 2022.
  • GAAP net income was $21.2 million in the third quarter of 2023, compared to $22.5 million in the third quarter of 2022.
  • GAAP diluted earnings per share (“EPS”) was $0.59 in the third quarter of 2023, compared to $0.63 in the third quarter of 2022.
  • Adjusted Diluted EPS was $0.85 in the third quarter of 2023, compared to $0.81 in the third quarter of 2022.

Remote Patient Monitoring (RPM) Market Worth $41.7 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, November 7, 2023
Cloud, RPM, Stroke, GE HealthCare, Infection, Physician, Prevalence, Workforce, Diabetes, Application, Software, Abbott Laboratories, Sleep, Epidemic, Pulse, Boston Scientific, Risk, Telehealth, Partnership, Telecommunications, Remote patient monitoring, Medidata Solutions, OMRON, Vital signs, Collection, Investment, Market development, Patient, Public utility, Nursing, Hospital, Medical imaging, Medical device, Risk management, Asset management, Oracle, Medtronic

The program will feature VitalSight, OMRON's first remote patient monitoring service designed specifically for patients afflicted by high blood pressure and especially those with uncontrolled Stage 2 hypertension.

Key Points: 
  • The program will feature VitalSight, OMRON's first remote patient monitoring service designed specifically for patients afflicted by high blood pressure and especially those with uncontrolled Stage 2 hypertension.
  • These companies have emerged as other players due to their products and various strategic investments undertaken in the remote patient monitoring space.
  • Remote Patient Monitoring (RPM) Market - Key Benefits of Buying the Report:
    The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.
  • Market Diversification: Exhaustive information about new devices and software, growing geographies, recent developments, and investments in the remote patient monitoring Market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the remote patient monitoring Market.

Remote Patient Monitoring (RPM) Market Worth $41.7 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, November 7, 2023
Cloud, RPM, Stroke, GE HealthCare, Infection, Physician, Prevalence, Workforce, Diabetes, Application, Software, Abbott Laboratories, Sleep, Epidemic, Pulse, Boston Scientific, Risk, Telehealth, Partnership, Telecommunications, Remote patient monitoring, Medidata Solutions, OMRON, Vital signs, Collection, Investment, Market development, Patient, Public utility, Nursing, Hospital, Medical imaging, Medical device, Risk management, Asset management, Oracle, Medtronic

The program will feature VitalSight, OMRON's first remote patient monitoring service designed specifically for patients afflicted by high blood pressure and especially those with uncontrolled Stage 2 hypertension.

Key Points: 
  • The program will feature VitalSight, OMRON's first remote patient monitoring service designed specifically for patients afflicted by high blood pressure and especially those with uncontrolled Stage 2 hypertension.
  • These companies have emerged as other players due to their products and various strategic investments undertaken in the remote patient monitoring space.
  • Remote Patient Monitoring (RPM) Market - Key Benefits of Buying the Report:
    The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.
  • Market Diversification: Exhaustive information about new devices and software, growing geographies, recent developments, and investments in the remote patient monitoring Market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the remote patient monitoring Market.

Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study

Retrieved on: 
Thursday, November 2, 2023
Ebola, Virulence, Central Africa, Headache, Rocky Mountain Laboratories, Therapy, Vomiting, Diarrhea, Maxwell, Internal bleeding, Fever, Shock, Growth, Epidemic, Fatigue, RML, Biosafety level, Death, Peptide, BSL, EVD, Disease, Vaccine

The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.

Key Points: 
  • The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.
  • Once a human is infected, Ebola virus disease can be lethal within 4-5 days.
  • Maxwell is currently developing its Claromer drug platform, which has the potential to replace almost all antibiotics, antifungals and antivirals.
  • Since the first outbreak in Africa in 1976, several outbreaks and epidemics of Ebola virus have occurred in Western and Central Africa.